TX 000045
Alternative Names: TX-000045; TX-45Latest Information Update: 27 Sep 2024
At a glance
- Originator Tectonic Therapeutic
- Class Immunoglobulin Fc fragments; Peptide hormones; Recombinant fusion proteins
- Mechanism of Action RXFP1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension
- Phase I Cardiovascular disorders; Lung disorders
Most Recent Events
- 19 Sep 2024 Pharmacokinetics data from a preclinical study in Pulmonary arterial hypertension released by Tectonic Therapeutic
- 01 Aug 2024 Phase-II clinical trials in Pulmonary arterial hypertension (IV) (Tectonic Therapeutic pipeline, August 2024)
- 01 Aug 2024 Phase-II clinical trials in Pulmonary arterial hypertension (SC) (Tectonic Therapeutic pipeline, August 2024)